Hatzakis A, Polychronaki H, Miriagou V, Yannitsiotis A, Chrispeels J, Troonen H, Karafoulidou A, Gialeraki A, Katsouyanni K, Mandalaki T
Department of Hygiene and Epidemiology, Athens University Medical School, Greece.
Vox Sang. 1992;63(3):204-9. doi: 10.1111/j.1423-0410.1992.tb05101.x.
The antibody responses and the prevalence patterns of antibodies to hepatitis C virus (anti-HCV) in a cohort of patients (n = 210) with bleeding disorders were studied using a first-generation and a second-generation enzyme immunoassays (EIA-1, EIA-2) as well as a second-generation recombinant immunoblot assay (RIBA-2). The anti-HCV prevalence as determined by EIA-1 and EIA-2 was 183/210 (87.1%) and 197/210 (93.8%), respectively (p = 0.0026). None of the 17 EIA-2(+)/EIA-1(-) samples was scored nonreactive by RIBA-2. At follow-up, samples of 123 patients were tested. Twenty-nine out of 111 patients reactive by EIA-1 seroreverted according to EIA-1 while the seroreversion rate with EIA-2 was 0 out of the 121 (p < 10(-8)). The anti-HCV prevalence by EIA-2 was 150/154 (97.4%) in anti-HIV-1-positive individuals and 47/56 (83.9%) in the anti-HIV-1-negative ones (p = 0.001). However, high assay signals (OD 492 nm > 2.0) were observed in 94/150 (62.7%) and 45/47 (95.7%) of the anti-HIV-1-positive and -negative patients, respectively (p = 10(-5)). The decreasing anti-HCV reactivity among anti-HIV-1-positive individuals was mainly due to diminishing c33c reactivity. Seroconversion to anti-HCV was observed in 3/7 (42.9%) cases with acute icteric non-A, non-B hepatitis by both EIA-1 and EIA-2, while the remaining 4 cases had detectable levels of anti-HCV 1-18 months before the acute episode.
采用第一代和第二代酶免疫分析法（EIA-1、EIA-2）以及第二代重组免疫印迹法（RIBA-2），对一组患有出血性疾病的患者（n = 210）的丙型肝炎病毒抗体反应及抗丙型肝炎病毒（抗-HCV）抗体的流行模式进行了研究。EIA-1和EIA-2测定的抗-HCV流行率分别为183/210（87.1%）和197/210（93.8%）（p = 0.0026）。17份EIA-2(+)/EIA-1(-)样本中，无一被RIBA-2判定为无反应性。在随访中，对123例患者的样本进行了检测。111例EIA-1反应性患者中，有29例根据EIA-1血清学反应转阴，而121例中EIA-2的血清学反应转阴率为0（p < 10(-8)）。在抗HIV-1阳性个体中，EIA-2测定的抗-HCV流行率为150/154（97.4%），在抗HIV-1阴性个体中为47/56（83.9%）（p = 0.001）。然而，分别在94/150（62.7%）的抗HIV-1阳性患者和45/47（95.7%）的抗HIV-1阴性患者中观察到高检测信号（OD 492 nm > 2.0）（p = 10(-5)）。抗HIV-1阳性个体中抗-HCV反应性的降低主要是由于c33c反应性的减弱。在3/7（42.9%）急性黄疸型非甲非乙型肝炎病例中，通过EIA-1和EIA-2均观察到抗-HCV血清学转换，而其余4例在急性发作前1 - 18个月可检测到抗-HCV水平。
